Aman Witch's questions to Dr Reddy's Laboratories Ltd (RDY) leadership • Q1 2026
Question
Aman Witch of Astute Investment Management questioned the competitiveness of Dr. Reddy's semaglutide API, the potential impact of an adverse court ruling in India on the Canada launch, and the flexibility to scale up manufacturing capacity.
Answer
CEO Erez Israeli expressed confidence that their scaled-up API will be cost-competitive with others, including those from China. He acknowledged that an adverse ruling in the Delhi High Court is primarily a risk for the Canadian launch timeline, not just the Indian one. He stated that while there is some upside to the guided 10-12 million pen capacity, doubling it in calendar '26 would not be possible.